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ELSEVIER 
Tacrolimus Without Antilymphocyte Induction Therapy Prevents 
Pancreas Loss From Rejection in 123 Consecutive Patients 
R.J. Corry, M.F. Egidi, R. Shapiro, A. Sugitani, HA Gritsch, M.L. Jordan, S.F. Dodson, CA Vivas, 
V.P. Scantlebury, A.S. Rao, J.J. Fung, and T.E. Starzl 
THERE HAS BEEN considerable controversy whether 
antilymphoid induction therapy is necessary in organ 
transplant recipients who receive tacrolimus-based immu-
nosuppression. 
METHODS 
This report analyzes 123 consecutive patients who received pan-
creas transplants between July 1994 and July 1997. 106 in combi-
nation with kidney transplantation. Immunosuppression included 
intravenous tacrolimus 0.05 mg/kg for 5 to 7 days followed by an 
initial oral dose of 0.15 mglkg twice a day. The tarcolimus dose was 
adjusted daily to achieve whole blood trough levels of 20 to 25 
nglmL (first 2 weeks), 15 to 20 by 1 month, 10 to 15 by 3 months, 
and 7 to 12 by 6 months. Patients also received tapering steroid 
doses and azathioprine during the first half of the series and 
mycophcnolate mofetil during the second half. I 
RESULTS 
Survival rates were patient 98%, kidney 94%, and pancreas 
83% (median follow-up 18 months). Three patients lost 
graft function at 6, 9, and 20 months from chronic rejection. 
One patient, who was highly sensitized and whose lympho-
cytotoxic cross-match turned positive postoperatively, lost 
the graft at 3 weeks from an antibody-mediated rejection. 
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Other losses were nonimmunologic, nine of which were 
secondary to an ischemic/reperfusion injury leading to 
thrombosis within a few days after transplantation. There 
were no losses from acute cellular rejection. 
SUMMARY 
In this series, antilymphoid induction therapy did not 
appear to be necessary to prevent early graft loss from 
rejection. In addition, we have followed cytomegalovirus 
(CMV) antigenemia (pp65) for CMV infection. Although 
some patients developed a positive antigenemia in the 
seropositive to negative donor-recipient combinations, only 
one patient had a prolonged febrile course for 1 week. 
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